12,372 trials
Infections, Streptococcal
Primary: Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 Microgram Per Millilitre (µg/mL). — 69; 90; 93; 94 Participants
Hypertension
Primary: Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough — 12.28; 3.14 mmHg — p=<0.0001
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week…
Hypertension
Primary: Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements. — 67.6 Percentage of participants
Perennial Allergic Rhinitis
Primary: The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment — 0.90; 0.95; 0.31 ratio
Factor XIII Deficiency
Primary: The Incidence of Spontaneous Bleeding Events Requiring Treatment (Treatment is Defined as Administration of a FXIII-Containing Product to Treat the Bleeding Event) — 0…
Alzheimer's Disease
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog) — 0.90; -0.58; -1.66 Scores on a scale — p=0.0113
Multiple Sclerosis
Primary: Change in Mean Pain Due to MS NRS Score — -2.02; -1.89 units on a scale — p=0.468
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -1.47; -1.31 percentage of total hemoglobin — p=0.017
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Time to Disease Progression (TTP) — 2.4; 1.2 years — p=0.02
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score — -11.3; -11.4 Units on a scale
Schizophrenia
Primary: Change From Baseline in the Total Positive and Negative Syndrome Scale (PANSS). — -9.1; 3.8; -9.9 scores on a scale — p=<0.0001
Overweight · Obesity
Primary: Change in Body Fat Mass — -2.7; -0.4 kg — p=0.001
Iliac Artery Stenosis
Primary: Device- and/or Procedure-related Major Adverse Events (MAE) — 3.4 percentage of participants — p=<0.0001
Stage II Peripheral Arterial Occlusive Disease · Intermittent Claudication Fontaine Stage II PAOD
Primary: Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline — 2.60; 1.98 meter/meter